These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35220954)

  • 1. Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome.
    Vinnat V; Chevret S
    BMC Med Res Methodol; 2022 Feb; 22(1):54. PubMed ID: 35220954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints.
    Shi H; Yin G
    Biometrics; 2018 Sep; 74(3):1055-1064. PubMed ID: 29466612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive enrichment trials: What are the benefits?
    Burnett T; Jennison C
    Stat Med; 2021 Feb; 40(3):690-711. PubMed ID: 33244786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.
    Park Y; Liu S; Thall PF; Yuan Y
    Biometrics; 2022 Mar; 78(1):60-71. PubMed ID: 33438761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian adaptive design with biomarkers for targeted therapies.
    Eickhoff JC; Kim K; Beach J; Kolesar JM; Gee JR
    Clin Trials; 2010 Oct; 7(5):546-56. PubMed ID: 20571131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Bayesian modeling in frequentist adaptive enrichment designs.
    Simon N; Simon R
    Biostatistics; 2018 Jan; 19(1):27-41. PubMed ID: 28520893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulation study for evaluating an adaptive-randomisation Bayesian hybrid trial design with enrichment.
    Vinnat V; Chiche JD; Demoule A; Chevret S
    Contemp Clin Trials Commun; 2023 Jun; 33():101141. PubMed ID: 37397429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-based Bayesian randomized clinical trial design for identifying a target population.
    Sugitani Y; Morita S; Nakakura A; Yamamoto H
    Stat Med; 2023 Jul; 42(16):2797-2810. PubMed ID: 37078122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
    Shan G; Zhang H; Jiang T
    BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.
    Brown AR; Gajewski BJ; Aaronson LS; Mudaranthakam DP; Hunt SL; Berry SM; Quintana M; Pasnoor M; Dimachkie MM; Jawdat O; Herbelin L; Barohn RJ
    Trials; 2016 Aug; 17(1):428. PubMed ID: 27577191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
    Berchialla P; Zohar S; Baldi I
    Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Design of an Adaptive Clinical Trial to Evaluate the Efficacy of Extra-Corporeal Membrane Oxygenation for Out-of-Hospital Cardiac Arrest.
    Tolles J; Kidwell KM; Broglio K; Graves T; Meurer W; Lewis RJ; Neumar RW
    Resuscitation; 2021 Jan; 158():185-192. PubMed ID: 33221363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
    Liu Y; Kairalla JA; Renfro LA
    Biometrics; 2022 Dec; 78(4):1441-1453. PubMed ID: 34415052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian adaptive clinical trial designs for respiratory medicine.
    Ryan EG; Couturier DL; Heritier S
    Respirology; 2022 Oct; 27(10):834-843. PubMed ID: 35918280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.